Skip to main content
. 2021 Jan;10(1):186–200. doi: 10.21037/gs-20-576

Table 2. Comparison between the Kimura and Warshaw technique.

Variable Kimura (n=41) Warshaw (n=11) P value
Age (years), n (%) 0.095
   <50 27 (65.9) 4 (36.4)
   ≥50 14 (34.1) 7 (63.6)
Sex, n (%) 0.159
   Female 29 (70.7) 5 (45.5)
   Male 12 (29.3) 6 (54.5)
BMI (kg/m2), n (%) 0.435
   <24 32 (78.0) 7 (63.6)
   ≥24 9 (22.0) 4 (36.4)
Tumor size (cm), n (%) 0.216
   <6 34 (82.9) 7 (63.6)
   ≥6 7 (17.1) 4 (36.4)
Tumor location, n (%) 0.453
   Body 12 (29.3) 3 (27.3)
   Tail 18 (43.9) 3 (27.3)
   Body and tail 11 (26.8) 5 (45.4)
Radiographic appearance, n (%) 0.000
   Solid 8 (19.5) 4 (36.4)
   Cystic 27 (65.9) 3 (27.3)
   Heterogeneous 6 (14.6) 4 (36.4)
Splenic vessel compression by tumor, n (%) 0.015
   Obvious 5 (12.2) 7 (63.6)
   No/slight 36 (87.8) 4 (36.4)
Pathological diagnosis, n (%) 0.326
   SCN 14 (34.1) 3 (27.3)
   MCN 8 (19.5) 2 (18.2)
   SPN 5 (12.2) 2 (18.2)
   NET 6 (14.6) 4 (36.4)
   Others 8 (19.5) 0 (0.0)
Operative time, mean ± SD (min) 226.0±56.1 228.2±56.7 0.909
EBL, median (IQR) (mL) 50 (20 to 100) 50 (20 to 100) 0.563
Conversion, n (%) 0 (0.0) 0 (0.0) N/A
LOS, mean ± SD (days) 8.2±6.8 10.8±5.6 0.250
Morbidity, n (%) 5 (12.2) 2 (18.2) 0.630
CR-POPF, n (%) 3 (7.3) 1 (9.1) 1.000
Mortality, n (%) 0 (0.0) 0 (0.0) N/A

RSPDP, robotic splenic preservation distal pancreatectomy; BMI, body mass index; SCN, serous cystic neoplasm; MCN, mucinous cystic neoplasm; SPN, solid pseudopapillary neoplasm; NET, neuroendocrine tumor; EBL, estimated blood loss; LOS, length of stay; CR-POPF, clinically relevant postoperative pancreatic fistula; N/A, not applicable.